» Articles » PMID: 37727135

The Correlation Between Clinical Outcomes and Genomic Analysis with High Risk Factors for the Progression of Osteosarcoma

Overview
Journal Mol Oncol
Date 2023 Sep 20
PMID 37727135
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is a rare but aggressive malignancy. Despite previous reports, molecular characterization of this disease is not well understood, and little is known regarding OS in Chinese patients. Herein, we analyzed the genomic signatures of 73 Chinese OS cases. TP53, NCOR1, LRP1B, ATRX, RB1, and TFE3 were the most frequently mutated gene in our OS cohort. In addition, the genomic analysis of Western OS patients was performed. Notably, there were remarkable disparities in mutational landscape, base substitution pattern, and tumor mutational burden between the Chinese and Western OS cohorts. Specific molecular mechanisms, including DNA damage repair (DDR) gene mutations, copy number variation (CNV) presence, aneuploidy, and intratumoral heterogeneity, were associated with disease progression. Additionally, 30.1% of OS patients carried clinically actionable alterations, which were mainly enriched in PI3K, MAPK, DDR, and RTK signaling pathways. A specific molecular subtype incorporating DDR alterations and CNVs was significantly correlated with distant metastasis-free survival and event-free survival, and this correlation was observed in all subgroups with different characteristics. These findings comprehensively elucidated the genomic profile and revealed novel prognostic factors in OS, which would contribute to understanding this disease and promoting precision medicine of this population.

Citing Articles

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.

Luo C, Min X, Zhang D Front Immunol. 2025; 15:1539696.

PMID: 39896817 PMC: 11782189. DOI: 10.3389/fimmu.2024.1539696.

References
1.
Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

2.
Chen D, Zhao Z, Huang Z, Chen D, Zhu X, Wang Y . Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018; 6:11. PMC: 5884797. DOI: 10.1038/s41413-018-0009-8. View

3.
Meftahpour V, Aghebati-Maleki A, Fotouhi A, Safarzadeh E, Aghebati-Maleki L . Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma. EXCLI J. 2022; 21:250-268. PMC: 8822307. DOI: 10.17179/excli2021-4094. View

4.
Tubbs A, Nussenzweig A . Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell. 2017; 168(4):644-656. PMC: 6591730. DOI: 10.1016/j.cell.2017.01.002. View

5.
Eichner L, Brun S, Herzig S, Young N, Curtis S, Shackelford D . Genetic Analysis Reveals AMPK Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models. Cell Metab. 2018; 29(2):285-302.e7. PMC: 6365213. DOI: 10.1016/j.cmet.2018.10.005. View